Format

Send to

Choose Destination
Ann N Y Acad Sci. 2017 Sep;1403(1):38-47. doi: 10.1111/nyas.13426.

Resveratrol and inflammatory bowel disease.

Author information

1
College of Food Science and Technology, Nanjing Agricultural University, Nanjing, Jiangsu, P. R. China.
2
State Key Laboratory of Food Science and Technology, Jiangnan University, Wuxi, Jiangsu, P. R. China.

Abstract

Inflammatory bowel disease (IBD) is a chronic inflammatory disease of the gastrointestinal tract, comprising ulcerative colitis (UC) and Crohn's disease (CD). Progression of IBD leads to long-term impairment of intestinal structure and function. The pathogenesis of IBD is complex, involving environmental, immunological, genetic, microbial, and psychological factors. The conventional therapies and many existing biopharmaceuticals for IBD have limited efficacy or adverse effects. As a promising safe and effective therapy for IBD, resveratrol has been studied widely, as it has shown anti-inflammatory and antioxidant activity. Resveratrol's mechanism of action involves multiple immune responses and signaling pathways; it is absorbed quickly and metabolized into various derivatives. However, the poor water solubility and low bioavailability of resveratrol limit its clinical applications. Further research should attempt to improve the stability and oral bioavailability of resveratrol by modification and various delivery systems.

KEYWORDS:

bioavailability; inflammatory bowel disease; mechanism; metabolites; resveratrol

PMID:
28945937
DOI:
10.1111/nyas.13426
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center